Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M610854200 on February 28, 2007

J. Biol. Chem., Vol. 282, Issue 17, 12893-12906, April 27, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/17/12893    most recent
M610854200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, B. W.
Right arrow Articles by Hinkle, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, B. W.
Right arrow Articles by Hinkle, P. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phosphorylation of the Endogenous Thyrotropin-releasing Hormone Receptor in Pituitary GH3 Cells and Pituitary Tissue Revealed by Phosphosite-specific Antibodies*Formula

Brian W. Jones, Gyun Jee Song, Emileigh K. Greuber, and Patricia M. Hinkle1

From the Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York 14642

To study phosphorylation of the endogenous type I thyrotropin-releasing hormone receptor in the anterior pituitary, we generated phosphosite-specific polyclonal antibodies. The major phosphorylation site of receptor endogenously expressed in pituitary GH3 cells was Thr365 in the receptor tail; distal sites were more phosphorylated in some heterologous models. beta-Arrestin 2 reduced thyrotropin-releasing hormone (TRH)-stimulated inositol phosphate production and accelerated internalization of the wild type receptor but not receptor mutants where the critical phosphosites were mutated to Ala. Phosphorylation peaked within seconds and was maximal at 100 nM TRH. Based on dominant negative kinase and small interfering RNA approaches, phosphorylation was mediated primarily by G protein-coupled receptor kinase 2. Phosphorylated receptor, visualized by immunofluorescence microscopy, was initially at the plasma membrane, and over 5-30 min it moved to intracellular vesicles in GH3 cells. Dephosphorylation was rapid (t1/2 ~ 1 min) if agonist was removed while receptor was at the surface. Dephosphorylation was slower (t1/2 ~ 4 min) if agonist was withdrawn after receptor had internalized. After agonist removal and dephosphorylation, a second pulse of agonist caused extensive rephosphorylation, particularly if most receptor was still on the plasma membrane. Phosphorylated receptor staining was visible in prolactin- and thyrotropin-producing cells in rat pituitary tissue from untreated rats and much stronger in tissue from animals injected with TRH. Our results show that the TRH receptor can rapidly cycle between a phosphorylated and nonphosphorylated state in response to changing agonist concentrations and that phosphorylation can be used as an indicator of receptor activity in vivo.


Received for publication, November 24, 2006 , and in revised form, February 12, 2007.

* This work was supported by National Institutes of Health (NIH) Grant DK19974 (to P. M. H.), an NIH cardiovascular research training grant and a Pharmaceutical Manufacturers' Association predoctoral fellowship (to B. W. J.), and an Endocrine Society Summer Research Fellowship (to E. K. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1-4.

1 To whom correspondence should be addressed: Dept. of Pharmacology and Physiology, University of Rochester Medical Center, Box 711, Rochester, NY 14642. Tel.: 585-275-4933; Fax: 585-273-2652; E-mail: Patricia_Hinkle{at}urmc.rochester.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H. Nafisi, B. Banihashemi, M. Daigle, and P. R. Albert
GAP1(IP4BP)/RASA3 Mediates G{alpha}i-induced Inhibition of Mitogen-activated Protein Kinase
J. Biol. Chem., December 19, 2008; 283(51): 35908 - 35917.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. W. Jones and P. M. Hinkle
Arrestin Binds to Different Phosphorylated Regions of the Thyrotropin-Releasing Hormone Receptor with Distinct Functional Consequences
Mol. Pharmacol., July 1, 2008; 74(1): 195 - 202.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. A. Sebag and P. M. Hinkle
Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers
PNAS, December 18, 2007; 104(51): 20244 - 20249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement